The rapid rise of GLP-1 medications like Wegovy and Ozempic has created what many in the benefits industry are calling a gold rush. For business owners in British Columbia, Alberta, and Saskatchewan, this surge in demand presents a complex dilemma: how do you support the genuine health needs of your employees without compromising the long-term financial stability of your group benefits plan? As we move through 2026, the conversation has shifted from the science of weight loss to the hard reality of plan sustainability and the imminent arrival of lower-cost alternatives.
The Scale of the Demand
Weight management has long been viewed through the lens of lifestyle, but the medical community in Western Canada has increasingly recognized obesity as a chronic disease. This shift, combined with the high visibility of GLP-1 drugs on social media, has led to an explosion in claims. In 2024 and 2025, we saw these medications become the single largest cost driver for many private plans. For a small to mid-sized business in Calgary or Saskatoon, a handful of employees on a $5,000-a-year medication can result in a double-digit premium increase at renewal.
The dilemma for the employer is rooted in empathy. You want your team to be healthy. We know that effective weight management reduces the risk of heart disease, diabetes, and certain cancers. However, unlike a short course of antibiotics, GLP-1s are often long-term or even lifelong commitments. This creates a permanent, high-cost line item on your benefits budget that many plans were never designed to absorb.
The Western Canadian Regulatory Landscape
As of March 2026, the provincial health systems in BC, Alberta, and Saskatchewan have taken a cautious approach to these drugs for weight loss. While BC PharmaCare and the Alberta and Saskatchewan drug plans generally cover GLP-1s for Type 2 Diabetes, they have not broadly expanded coverage to include obesity as a standalone indication.
In late 2025, BC PharmaCare reviewed the clinical evidence for Wegovy but ultimately declined to add it to the public formulary for weight management due to the high price demanded by the manufacturer. This leaves the burden almost entirely on private insurance. In Alberta, the provincial government’s focus on coordinating public and private spending has meant that most Albertans still rely on their employer-sponsored plans for these prescriptions. Saskatchewan follows a similar path, where the private market is the primary gateway for access to anti-obesity medications.
The 2026 Shift: Generics and Competition
The “gold rush” is entering a new phase this year because the patent landscape has changed. In January 2026, the data exclusivity for semaglutide expired in Canada. We are currently in the window where several generic manufacturers are awaiting Health Canada approval for their versions of these medications.
By the third quarter of 2026, we expect to see generic semaglutide on pharmacy shelves at a fraction of the current brand-name cost. Early projections suggest these generics could be priced at approximately 35 percent of the original cost. Additionally, we have seen the arrival of secondary brands like Poviztra, which are essentially the same medication sold at a lower price point to compete with the generics. For employers, this is the light at the end of the tunnel. The challenge is bridge-funding your plan until these lower-cost options become the standard.
Managing the Dilemma: Strategic Workarounds
To survive the current cost pressures while waiting for generics, many Western Canadian businesses are adopting a three-tiered strategy.
First, the implementation of annual maximums. Rather than an open-ended drug benefit, many plans in BC and the Prairies now include a specific cap on anti-obesity medications—often around $2,000 to $2,500 per year. This allows the employee to access the medication but shares the cost burden once the cap is reached, protecting the employer from unlimited liability.
Second, strict prior authorization. Most insurance carriers now require a detailed medical questionnaire to ensure the drug is being used for a clinical need rather than cosmetic weight loss. This involves verifying a Body Mass Index (BMI) threshold or the presence of comorbidities like high blood pressure.
Third, the transition to generic-only or “lowest-cost alternative” pricing. By adjusting your plan design now to state that the plan will only pay the price of the lowest-cost version, you automatically prepare your budget for the arrival of generics later this year.
Finding the Balance
The GLP-1 gold rush is a test of a company’s benefits philosophy. If you choose to exclude these drugs entirely, you may save money in the short term but face higher disability and chronic disease costs down the road. If you cover them without limits, you risk the solvency of the plan.
In 2026, the smartest move for an employer in Western Canada is to maintain access through a controlled, capped, and medically verified framework. This demonstrates a commitment to employee health while acknowledging that the business must remain viable. As generics become available over the next few months, the “dilemma” will likely ease, but the lessons we’ve learned about plan sustainability will remain relevant for years to come.